世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のバイオマーカー市場予測 2017-2027年

Global Biomarkers Market Forecast 2017-2027

Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases

 

出版社 出版年月価格 ページ数図表数
Visiongain
ヴィジョンゲイン社
2017年10月お問い合わせください 206 125

サマリー

Report Details

The global biomarkers market is expected to grow at a CAGR of 9.1% in the first half of the forecast period. In 2016, the largest sector of the market was biomarker discovery, which encompasses revenues for instruments and reagents, as well as the other costs associated with in-house biomarker research and development. This sector accounted for 49.3% of the global biomarkers market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 206-page report you will receive 66 tables and 59 figures– all unavailable elsewhere.

The 206-page report provides clear detailed insight into the global biomarkers market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Biomarkers Market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the global biomarkers market by Sector:
- Biomarker Services
- Biomarker Diagnostics
- Biomarker Discovery

• This report also breaks down the revenue forecast for the global biomarkers market by Discipline:
- Genomics
- Proteomics
- Bioinformatics
- Other

• This report also breaks down the revenue forecast for the global biomarkers market by Therapeutic Indication:
- Cancer
- Cardiovascular Diseases
- CNS,
- Autoimmune Diseases
- Other

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
- US
- EU5 (further segmented into France, Germany, the UK, Spain and Italy)
- Japan
- China
- India
- Russia
- Brazil
- RoW

• Our study gives qualitative analysis of the biomarkers market. It includes a SWOT and STEP Analysis.

• Our study discusses the selected leading companies that are the major players in the biomarkers industry. These companies are biomarker service providers, biomarker technology providers and biomarker diagnostic developers:
- Quintiles IMS Holdings Inc
- Laboratory Corporation of America Holdings
- Parexel
- Charles River Laboratories
- ICON plc
- WuXi PharmaTec
- Caprion Proteomics
- Proteome Sciences
- Pacific Biomarkers
- Oxford Gene Technology (OGT)
- Worldwide Clinical Trials (WWC)
- Agilent
- AB SCIEX
- QIAGEN
- Axela Inc
- Thermo Fisher Scientific
- Quest Diagnostics
- Myriad Genetics
- Genomic Health
- Critical Diagnostics
- Epigenomics
- MDxHealth (formerly OncoMethylome)

• Our study also discusses activities of the big pharmaceutical companies that are investing in biomarkers development through, for example, collaborations with CROs:
- Pfizer
- Novartis
- Roche Diagnostics
- Ventana Medical Systems
- Merck & Co.
- Sanofi
- GSK
- Abbott Laboratories
- AstraZeneca

Visiongain’s study is intended for anyone requiring commercial analyses for the global biomarkers market. You find data, trends and predictions.

Buy our report today Global Biomarkers Market Forecast 2017-2027: Biomarker Services, Biomarker Diagnostics, Biomarker Discovery, Genomics, Proteomics, Bioinformatics, Cancer, Cardiovascular Diseases, CNS, Autoimmune Diseases.



目次

Table of Contents

1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 The Global Burden of Eye Disease
2.3 Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the ‘Silent Thief of Sight’
2.4.1 A Classification of Glaucoma
2.4.1.1 Primary Open-Angle Glaucoma
2.4.1.2 Acute Angle-Closure Glaucoma
2.4.1.3 Congenital Glaucoma
2.4.1.4 Secondary Glaucoma
2.4.1.5 Normal-Tension Glaucoma
2.4.1.6 Ocular Hypertension
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry (non-exudative) AMD
2.5.2 Wet (exudative) AMD
2.5.3 Risk Factors for AMD
2.5.4 Diagnosis of AMD
2.5.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome
2.11 Phases of Clinical Trials
2.12 Currency Exchange Rates in This Report

3. Ophthalmic Drugs: World Market 2016-2026
3.1 The World Ophthalmic Drugs Market in 2015
3.2 World Ophthalmic Drugs Market: Sales Forecast 2016-2026
3.3 Leading Ophthalmic Drugs
3.4 Leading Companies in the Ophthalmic Drugs Market
3.4.1 Top 25 Ophthalmic Drug Manufacturers
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2016-2026
3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2016-2026
3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2016-2026
3.5.3 Glaucoma Drugs Market: Sales Forecast 2016-2026
3.5.4 Dry Eye Drugs Market: Sales Forecast 2016-2026
3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2016-2026
3.6 How Will Market Shares Change to 2026?
3.7 World Ophthalmic Drugs Market: Drivers and Restraints 2016-2026
3.7.1 World Ophthalmic Drugs Market: Analysis of Drivers
3.7.2 World Ophthalmic Drugs Market: Analysis of Restraints

4. Leading US Ophthalmic Drug Manufacturers 2016-2026
4.1 Allergan Overview
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.1.1 Restasis: Generic Launch in 2016?
4.1.1.2 Restasis: Sales Forecast 2016-2026
4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries
4.1.1.4 Lumigan and Ganfort: Sales Forecast 2016-2026
4.1.1.5 Refresh Brand Products: the Range
4.1.1.6 Alphagan/Alphagan P and Combigan: Extended Lifecycle
4.1.1.7 Alphagan/Alphagan P and Combigan: Sales Forecast 2016-2026
4.1.1.8 Acular: New Forms Receiving FDA Approvals
4.1.1.9 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Edema
4.1.2 Allergan: Late Stage Ophthalmic Product Pipeline
4.1.3 Allergan: Ophthalmic Revenue Forecast 2016-2026
4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2016-2026
4.1.4 Allergan: SWOT Analysis
4.2 Pfizer Overview
4.2.1 Pfizer: Ophthalmic Product Portfolio
4.2.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster
4.2.1.2 Xalatan/Xalacom: Sales Forecast 2016-2026
4.2.2 Pfizer: Ophthalmic Product Pipeline
4.2.3 Pfizer: Revenue Forecast 2016-2026
4.2.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2016-2026
4.2.4 Pfizer: SWOT Analysis
4.3 Regeneron Overview
4.3.1 Regeneron: Ophthalmic Product Portfolio
4.3.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.3.1.2 Eylea: US Sales Forecast 2016-2026
4.3.2 Regeneron: Ophthalmic Product Pipeline
4.3.3 Regeneron: Revenue Forecast 2016-2026
4.3.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2016-2026
4.3.4 FDA Approves Zaltrap (aflibercept)
4.3.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
4.3.6 Regeneron: SWOT Analysis
4.4 Akorn Overview
4.4.1 Akorn: Ophthalmic Product Portfolio
4.4.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales
4.4.1.2 Cosopt/Cosopt PF: Acquired from Merck
4.4.2 Akorn: Revenue Forecast 2016-2026
4.4.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2016-2026
4.4.3 Akorn: SWOT Analysis

5. Leading European Ophthalmic Drug Manufacturers 2016-2026
5.1 Bayer Overview
5.1.1 Bayer: Ophthalmic Product Pipeline
5.1.2 Eylea: non-US Sales Forecast 2016-2026
5.1.3 Bayer: Revenue Forecast 2016-2026
5.1.3.1 Bayer: Ophthalmic Drugs Market Share Forecast 2016-2026
5.2 Novartis (including Alcon) Overview
5.2.1 Novartis: Ophthalmic Product Portfolio
5.2.1.1 Lucentis: Still a Leading Drug in AMD
5.2.1.2 Lucentis: Non-US Sales Forecast 2016-2026
5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval
5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2016-2026
5.2.1.5 Vigamox: Competes with Alcon’s Moxeza
5.2.1.6 Vigamox: Sales Forecast 2016-2026
5.2.1.7 Azopt: Marketed in Major Markets
5.2.1.8 Azopt: Sales Forecast 2016-2026
5.2.1.9 Jetrea: Sales Revenues Fall Short
5.2.1.10 Jetrea: Non-US Sales Forecast 2016-2026
5.2.2 Novartis: Ophthalmic Product Pipeline
5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)
5.2.2.2 AKB 9778 (Aerpio Therapeutics)
5.2.3 Novartis: Revenue Forecast 2016-2026
5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2016-2026
5.2.4 Novartis: SWOT Analysis
5.3 Roche Overview
5.3.1 Roche: Ophthalmic Product Portfolio
5.3.1.1 Lucentis: US Sales Forecast 2016-2026
5.3.1.2 Avastin: Off-Label Use for Wet AMD Cannibalising Lucentis Sales
5.3.1.3 Avastin: Sales Forecast 2016-2026
5.3.2 Roche: Ophthalmic Product Pipeline
5.3.2.1 Lampalizumab (RG7417)
5.3.3 Roche: Revenue Forecast 2016-2026
5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2016-2026
5.3.4 Roche: SWOT Analysis

6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2016-2026
6.1 Santen Overview
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.1.1 Eylea: Japan Sales Forecast 2016-2026
6.1.1.2 Hyalein
6.1.1.3 Hyalein: Sales Forecast 2016-2026
6.1.1.4 Cosopt: Non-US Sales Forecast 2016-2026
6.1.1.5 Tapros/Taflotan: Sales Forecast 2016-2026
6.1.1.6 Diquas: Sales Forecast 2016-2026
6.1.1.7 Cravit: Higher Concentration Showing Significant Efficacy
6.1.1.8 Cravit: Sales Forecast 2016-2026
6.1.1.9 Alesion: Sales Forecast 2016-2026
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2016-2026
6.1.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2016-2026
6.1.4 Santen: SWOT Analysis
6.2 Senju Overview
6.2.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.2.1 Y 39983 (SNJ 1656)
6.2.2.2 Difluprednate (SJE-2079)
6.2.3 Senju: Revenue Forecast 2016-2026
6.2.3.1 Senju: Ophthalmic Drugs Market Share Forecast 2016-2026
6.2.4 Senju: SWOT Analysis
6.3 Valeant Overview
6.3.1 Valeant: Ophthalmic Product Portfolio
6.3.1.1 Lotemax: New Formulation Launch Expected in 2016
6.3.1.2 Lotemax: Sales Forecast 2016-2026
6.3.2 Valeant: Ophthalmic Product Pipeline
6.3.2.1 Vesneo (Latanoprostene Bunod)
6.3.2.2 Brimonidine tartarate 0.0025% for Eye Whitening (Valeant)
6.3.3 Valeant: Revenue Forecast 2016-2026
6.3.3.1 Valeant: Ophthalmic Drugs Market Share Forecast 2016-2026
6.3.4 Valeant: SWOT Analysis
6.3.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
6.3.4.2 Valeant: Difficult End to 2015 Puts Company Future in Doubt

7. Emerging Ophthalmic Drug Manufacturers in 2016
7.1 Companies with Small Ophthalmic Portfolios and Promising Pipeline Candidates, 2016
7.2 Acucela
7.3 Aerie Pharmaceuticals
7.4 Aerpio Therapeutics: Developing AKB 9778
7.5 Alimera Sciences
7.5.1 Iluvien: Increasing Geographical Reach and Increasing Sales
7.5.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.6 Amakem
7.7 Ampio Pharmaceuticals
7.8 Chengdu Kanghong Pharmaceutical
7.9 Eleven Biotherapeutics
7.10 EyeGate Pharmaceuticals
7.11 Gene Signal
7.11.1 Aganirsen: Preventing Corneal Graft Rejection
7.12 Icon Bioscience
7.13 MacuCLEAR
7.13.1 MC 1101: a Potential Therapy for Dry AMD
7.14 Neurotech
7.15 Omeros
7.16 OphthaliX (Can-Fite BioPharma)
7.17 Ophthotech
7.17.1 Fovista: Potential Game-Changer in AMD
7.17.2 Fovista: Significant Improvement on Lucentis in Phase II Trials
7.17.3 Zimura: Complement C5 Inhibitor
7.18 Otsuka Pharmaceutical
7.19 pSivida Corp.
7.20 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.21 Shire
7.21.1 Lifitegrast (SHP606) for Dry Eye
7.21.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.22 ThromboGenics
7.22.1 Jetrea (ocriplasmin)
7.22.2 ThromboGgenics: Leading Diabetic Eye Disease Pipeline

8. Qualitative Analysis of the Ophthalmic Drugs Market 2016-2026
8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium]
8.1.2 Threat of New Entrants [Low]
8.1.3 Power of Suppliers [Low]
8.1.4 Power of Buyers [Medium]
8.1.5 Threat of Substitutes [Medium]

9. Conclusions
9.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
9.2 The World Ophthalmic Drugs Market in 2015
9.2.1 Leading Ophthalmic Drugs Market Segments
9.2.2 Leading Ophthalmic Drugs
9.2.3 Leading Ophthalmic Drugs Companies
9.3 World Ophthalmic Drugs Market Forecast 2016-2026
9.4 The Future of the Ophthalmic Drugs Market?
9.4.1 Increasing Revenue Concentration among Specialist Companies
9.4.2 The Rise of Generics
9.4.3 Small Companies Can Have a Big Impact
9.4.4 What Will Succeed in the Ophthalmic Drugs Market?

10. Glossary

Appendix
Visiongain’s Bespoke Research Service
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form

List of Tables
Table 2.1 ICD‑10 Classification of Visual Impairment, 2010
Table 2.2 Drug Treatments for Glaucoma, 2016
Table 2.3 Drug Treatments for AMD, 2016
Table 2.4 Drug Treatments for Ocular Allergy, 2016
Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2016
Table 2.6 Selected Drug Treatments for Eye Infections, 2016
Table 2.7 Clinical Trial Phases
Table 2.8 Currency Exchange Rates, 2015
Table 3.1 World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2015
Table 3.2 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2026
Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2015
Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Market Share (%), 2015
Table 3.5 Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2015
Table 3.6 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2015-2026
Table 3.7 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2026
Table 3.8 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 3.9 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 3.10 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 3.11 Other Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2026
Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2015, 2020 and 2026
Table 4.1 Allergan: Overview, 2016
Table 4.2 Allergan: Ophthalmic Drug Products, Revenue ($m), Growth Rate (%), 2014 and 2015
Table 4.3 Allergan: Restasis Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.4 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.5 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.6 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.7 Allergan: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 4.8 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 4.9 Pfizer: Overview, 2016
Table 4.10 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.11 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.12 Pfizer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 4.13 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 4.14 Regeneron: Overview, 2016
Table 4.15 Regeneron: Eylea Revenue ($m), AGR (%) and CAGR(%) 2015-2026
Table 4.16 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.17 Regeneron: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 4.18 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 4.19 Akorn: Overview, 2016
Table 4.20 Akorn: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.21 Akorn: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 4.22 Akorn: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 5.1 Bayer: Overview, 2016
Table 5.2 Bayer: Eylea Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.3 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.4 Bayer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 5.5 Novartis: Overview, 2016
Table 5.6 Novartis: Lucentis Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.7 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.8 Novartis: Vigamox Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.9 Novartis: Azopt Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.10 Novartis: Jetrea Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.11 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.12 Novartis: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 5.13 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2015-2025
Table 5.14 Roche: Overview, 2016
Table 5.15 Roche: Lucentis Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.16 Roche: Avastin Ophthalmic Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.17 Roche: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.18 Roche: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 5.19 Roche: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 6.1 Santen: Overview, 2016
Table 6.2 Santen: Revenue ($m) and Revenue Share (%) by Segment, FY 2015
Table 6.3 Santen: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Date, Region, 2016
Table 6.4 Santen: Major Prescription Ophthalmic Drugs, Revenue ($m), Revenue Share (%), FY 2015
Table 6.5 Santen: Eylea Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.6 Santen: Hyalein Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.7 Santen: Cosopt Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.8 Santen: Tapros/Taflotan Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.9 Santen: Diquas Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.10 Santen: Cravit Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.11 Santen: Alesion Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.12 Santen: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.13 Santen: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 6.14 Santen: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 6.15 Senju: Overview, 2016
Table 6.16 Senju: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Year, 2015
Table 6.17 Senju: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.18 Senju: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 6.19 Senju: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 6.20 Valeant: Overview, 2016
Table 6.21 Valeant: Lotemax Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.22 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.23 Valeant: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 6.24 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 7.1 Otsuka Pharmaceutical: Overview of Ophthalmic Drug Pipelines, Drug Type, Indication, Country, 2015
Table 9.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), 2015, 2020 and 2026

List of Figures
Figure 1.1 Global Causes of Visual Impairment (% of cases), 2012
Figure 1.2 World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2015-2026
Figure 1.3 Global Ophthalmic Drugs Market Segmentation Overview, 2016
Figure 2.1 Estimated Global Prevalence of Visual Impairment (millions of people), 2010
Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2013
Figure 2.3 Global Causes of Visual Impairment (% of cases), 2013
Figure 2.4 Classification of Glaucoma, 2016
Figure 2.5 Global Causes of Blindness (% of cases), 2013
Figure 3.1 World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2015
Figure 3.2 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2015
Figure 3.3 World Ophthalmic Drugs Market Forecast: Revenue ($m) and AGR(%), 2015-2026
Figure 3.4 Top 10 Ophthalmic Drugs: Market Share (%), 2015
Figure 3.5 Top 10 Ophthalmic Drugs: Revenues ($m), 2015
Figure 3.6 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenues ($m), 2015
Figure 3.7 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2015
Figure 3.8 Retinal Disorders Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 3.9 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), 2015-2026
Figure 3.10 Glaucoma Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 3.11 Dry Eye Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 3.12 Other Ophthalmic Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 3.13 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2015
Figure 3.14 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2020
Figure 3.15 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2026
Figure 3.16 World Ophthalmic Drugs Market: Drivers and Restraints, 2016-2026
Figure 4.1 Allergan: Restasis Revenue ($m) and AGR (%), 2015-2026
Figure 4.2 Allergan: Lumigan and Ganfort Revenue ($m) and AGR (%), 2015-2026
Figure 4.3 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m) and AGR (%), 2015-2026
Figure 4.4 Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2015-2026
Figure 4.5 Allergan: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
Figure 4.6 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), 2015-2026
Figure 4.7 Pfizer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2015-2026
Figure 4.8 Pfizer: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
Figure 4.9 Regeneron: Eylea Revenue ($m) and AGR(%), 2015-2026
Figure 4.10 Regeneron: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 4.11 Regeneron: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
Figure 4.12 Akorn: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 4.13 Akorn: Ophthalmic Drugs Market Share (%), 2015-2026
Figure 5.1 Bayer: Eylea Revenue ($m) and AGR(%), 2015-2026
Figure 5.2 Bayer: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 5.3 Bayer: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
Figure 5.4 Novartis: Lucentis Revenue ($m) and AGR(%), 2015-2026
Figure 5.5 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m) and AGR(%), 2015-2026
Figure 5.6 Novartis: Vigamox Revenue ($m) and AGR(%), 2015-2026
Figure 5.7 Novartis: Azopt Revenue ($m) and AGR(%), 2015-2026
Figure 5.8 Novartis: Jetrea Revenue ($m) and AGR(%), 2014-2025
Figure 5.9 Novartis: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 5.10 Novartis: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
Figure 5.11 Roche: Lucentis Revenue ($m) and AGR(%), 2015-2026
Figure 5.12 Roche: Avastin Ophthalmic Revenue ($m) and AGR(%), 2015-2026
Figure 5.13 Roche: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 5.14 Roche: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2015
Figure 6.2 Santen: Major Prescription Ophthalmic Drugs, Revenue Share (%), FY 2015
Figure 6.3 Santen: Eylea Revenue ($m) and AGR(%), 2015-2026
Figure 6.4 Santen: Hyalein Revenue ($m) and AGR(%), 2015-2026
Figure 6.5 Santen: Cosopt Revenue ($m) and AGR(%), 2015-2026
Figure 6.6 Santen: Tapros/Taflotan Revenue ($m) and AGR(%), 2015-2026
Figure 6.7 Santen: Diquas Revenue ($m) and AGR(%), 2015-2026
Figure 6.8 Santen: Cravit Revenue ($m) and AGR(%), 2015-2026
Figure 6.9 Santen: Alesion Revenue ($m) and AGR(%), 2015-2026
Figure 6.10 Santen: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 6.11 Santen: Ophthalmic Drugs Market Share (%), 2015-2026
Figure 6.12 Senju: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 6.13 Senju: Ophthalmic Drugs Market Share (%), 2015-2026
Figure 6.14 Valeant: Lotemax Revenue ($m) and AGR (%), 2015-2026
Figure 6.15 Valeant: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 6.16 Valeant: Ophthalmic Drugs Market Share (%), 2015-2026
Figure 7.1 Gene Signal: Ophthalmic Drug Pipeline Progress, 2016
Figure 7.2 Ophthotech: Ophthalmic Drug Pipeline Progress, 2015
Figure 7.3 Otsuka Pharmaceutical: Ophthalmic Drug Pipeline Progress, 2016
Figure 7.4 Shire: Ophthalmic Drug Pipeline Progress, 2016
Figure 8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market, 2016-2026
Figure 9.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), 2015, 2020 and 2026

Companies Listed

Actavis
Acucela
Advanced Vision Research
Aerie Pharmaceuticals
Aerpio Therapeutics, Inc
Alcon
Akorn
Algeta
Alimera Sciences
Allergan
Allegro Ophthalmics
Amakem
Ampio Pharmaceuticals
Asahi Glass
Aton Pharma, Inc.
Aventis
AYUMI Pharmaceutical Corporation
Banyu Pharmaceutical
Barr Laboratories
Bausch & Lomb
Bayer AG
Bayer HealthCare
Bayer Yakuhin
Bristol-Myers Squibb
Can-Fite BioPharma
Chiron Corporation
Chugai Pharmaceutical
Ciba-Geigy
Ciba Vision
Chengdu Kanghong Pharmaceutical
Eleven Biotherapeutics
Eli Lilly
EyeGate Pharmaceuticals
Eyetech Inc.
Fougera Pharmaceuticals
Genentech
Gene Signal
GSK
Hi-Tech
Hospira Inc
ICN Pharmaceuticals
Icon Bioscience
Inception Sciences, Inc.
InSite Vision
Inspire Pharmaceuticals
ISTA Pharmaceuticals
Jenapharm
Kestrel Ophthalmics
King Pharmaceuticals
Kyorin Pharmaceutical
Kyowa Hakko Kirin
LEO Pharma
MacuCLEAR
MacuSight, Inc.
MAP Pharmaceuticals
MEAgate International FZLLC
Meda
Medicis Corporation
Merck & Co.
MerLion
MSD K.K.
Mystic Pharmaceuticals
Nestlé
Neurotech
Nippon Boehringer Ingelheim Co.,Ltd.
NovaBay Pharmaceuticals
Novagali Pharma
Novartis International AG
Novartis Institutes for BioMedical Research
Novartis Venture Funds
OcuSciences
Omeros
OphthtaliX
Ophthotech
Ora, Inc.
Otsuka Pharmaceutical
Parke-Davis
Par Pharmaceutical
Pfizer Inc.
Pharmacia
Philidor
PreCision Dermatology
Premacure
Procter & Gamble
pSivida Corp.
Quark Pharmaceuticals
Regeneron
Rekitt Benckiser
Roche Consumer Health
RXi Pharmaceuticals
Salix
Sandoz
Sanofi
Sanofi-Aventis
Santaris Pharma
Santen Pharmaceutical Co.
Santen S.A.S.
SARcode Bioscience
Schering AG
Senju Pharmaceutical Company Ltd.
Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd.
Senju USA Inc.
Shire
SkinMedica
Spark Therapeutics
Steigerwald
ThromboGenics
Upjohn
Valeant Pharmaceuticals International Ventana Medical Systems
Versant Ventures
VersaPharm
Warburg Pincus LLC
Warner-Lambert
Wyeth Pharmaceuticals
Zoetis
Organisations Mentioned in the Report
A*STAR Institute for Infocomm Research (Singapore)
American Academy of Ophthalmology (AAO)
American Diabetes Association
American Society of Retina Specialists (ASRS)
Association for Research in Vision and Ophthalmology (ARVO)
Emory University
European Medicines Agency (EMA)
Japanese Ministry of Health, Labour and Welfare (MHLW)
Japan Patent Office
Johns Hopkins University (Baltimore, US)
National Institute of Clinical Excellence (NICE)
National Institute of Health (NIH)
Ophthalmic Drugs Advisory Committee - Division of the FDA
Tokyo University of Science
UK National Health Service (NHS)
United Nations Department of Economic and Social Affairs, Population Division
US Food and Drug Agency (FDA)
US National Eye Institute (NEI)
US Preventive Services Task Force
World Health Organization (WHO)

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る